Charles River Laboratories International’s (CRL) “Outperform” Rating Reiterated at William Blair

Charles River Laboratories International (NYSE:CRL)‘s stock had its “outperform” rating reaffirmed by William Blair in a research report issued on Tuesday,Benzinga reports.

Several other equities research analysts also recently weighed in on CRL. StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. UBS Group boosted their target price on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Evercore ISI raised their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. Citigroup lowered shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and dropped their price objective for the company from $215.00 to $175.00 in a report on Tuesday, October 1st. Finally, CLSA downgraded Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a research report on Monday, November 18th. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Hold” and an average target price of $214.00.

Charles River Laboratories International Trading Down 6.3 %

Shares of NYSE CRL traded down $12.03 during trading hours on Tuesday, hitting $178.11. 1,050,715 shares of the company traded hands, compared to its average volume of 671,818. The company’s 50 day moving average price is $193.57 and its 200 day moving average price is $199.32. Charles River Laboratories International has a 12 month low of $175.61 and a 12 month high of $275.00. The stock has a market capitalization of $9.11 billion, a price-to-earnings ratio of 22.29, a price-to-earnings-growth ratio of 5.00 and a beta of 1.38. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. Charles River Laboratories International’s revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.72 EPS. On average, equities research analysts anticipate that Charles River Laboratories International will post 10.18 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in CRL. Versant Capital Management Inc lifted its position in shares of Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 150 shares in the last quarter. Wolff Wiese Magana LLC acquired a new position in Charles River Laboratories International in the 3rd quarter valued at $32,000. Assetmark Inc. lifted its holdings in Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 173 shares in the last quarter. ORG Wealth Partners LLC acquired a new stake in Charles River Laboratories International during the 4th quarter worth $56,000. Finally, Wilmington Savings Fund Society FSB purchased a new stake in shares of Charles River Laboratories International during the third quarter worth $59,000. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).